Sling Therapeutics Doses First Patients in P-III (ORBIT) Trial of Linsitinib for Thyroid Eye Disease

Shots: Sling Therapeutics has dosed the first patients in the global P-III (ORBIT) trial assessing linsitinib (150mg, PO, BID) vs PBO in ~130 adults with mod. to sev. active thyroid eye disease (TED) for 24wks. The trial will assess the proportion of proptosis responders at Wk. 24, defined as a ≥2 mm reduction in the…

ByRidhi Rastogi21 hours ago

Mereo BioPharma Reports P-III (ORBIT & COSMIC) Trials Findings on Setrusumab in Osteogenesis Imperfecta

Shots: Mereo BioPharma has reported setrusumab (UX143) results from the global P-III (ORBIT) trial vs PBO & P-III (COSMIC) trial vs bisphosphonates (IV) in 159 pts (5-25yrs.) & 69 pts (2 to <7 yrs.), respectively, with osteogenesis imperfecta Neither study met its 1EP of reduced annualized clinical fracture rate, but both showed statistically significant improvements…

ByRidhi RastogiDecember 30, 2025

Amgen and Kyowa Kirin Report Topline P-III (ASCEND) Study Results of Rocatinlimab in Moderate to Severe Atopic Dermatitis

Shots: The P-III (ASCEND) trial evaluated rocatinlimab (150 or 300mg, Q4W/Q8W) in ~2,600 atopic dermatitis pts who completed 24wks. in ROCKET trial program & continued for 32wks. in ASCEND, which will evaluate long-term safety & efficacy up to 104wks. Trial showed a favorable long-term safety profile (1EP) with low discontinuation rates due to AEs, consistent…

ByRidhi RastogiSeptember 9, 2025

Sling Therapeutics Doses First Patients in P-III (ORBIT) Trial of Linsitinib for Thyroid Eye Disease

Mereo BioPharma Reports P-III (ORBIT & COSMIC) Trials Findings on Setrusumab in Osteogenesis Imperfecta

Amgen and Kyowa Kirin Report Topline P-III (ASCEND) Study Results of Rocatinlimab in Moderate to Severe Atopic Dermatitis

Contact US

FOLLOW US